B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: Disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels

Arthritis Research and Therapy

Volumn 8, Issue 1, 2005, Pages

  Collins, Christopher E ^a   Gavin, Amanda L ^b   Migone, Thi Sau ^c   Hilbert, David M ^c   Nemazee, David ^b   Stohl, William ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 70350520105     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar1855     Document Type: Article

References (42)

1. Moore PA, Belvedere O, Orr A, Pieri K, LaFleur DW, Feng P, Soppet D, ChaMters M, Gentz R, Parmelee D, et al.: BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 1999, 285:260-263.
2. Schneider P, MacKay F, Steiner V, Hofmann K, Bodmer JL, Holler N, Ambrose C, Lawton P, Bixler S, Acha-Orbea H, et al.: BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 1999, 189:1747-1756.
3. Gross JA, Johnston J, Mudri S, Enselman R, Dillon SR, Madden K, Xu W, Parrish-Novak J, Foster D, Lofton-Day C, et al.: TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 2000, 404:995-999.
4. Mackay F, Woodcock SA, Lawton P, Ambrose C, Baetscher M, Schneider P, Tschopp J, Browning JL: Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999, 190:1697-1710.
5. Khare SD, Sarosi I, Xia XZ, McCabe S, Miner K, Solovyev I, Hawkins N, Kelley M, Chang D, Van G, et al.: Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. Proc Natl Acad Sci USA 2000, 97:3370-3375.
6. Kayagaki N, Yan M, Seshasayee D, Wang H, Lee W, French DM, Grewal IS, Cochran AG, Gordon NC, Yin J, et al.: BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-κB2. Immunity 2002, 17 515-524.
7. Zhang J, Roschke V, Baker KP, Wang Z, Alarcón GS, Fessler BJ, Bastian H, KimberlyARP, Zhou T: Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 2001, 166:6-10.
8. Cheema GS, Roschke V, Hilbert DM, Stohl W: Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 2001, 44:1313-1319.
9. Stohl W, Metyas S, Tan SM, Cheema GS, Oamar B, Xu D, Roschke V, Wu Y, Baker KP, Hilbert DM: B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: Longitudinal observations Arthritis Rheum 2003, 48:3475-3486.
10. Petri M, Stohl W, Chatham W, McCune W, Chevrier M, Shen Y-L, Zhong J, Orr A, Hall L, Freimuth W: Association of BLyS™ with measures of disease activity in a prospective SLE observational study. Arthritis Rheum 2004, 50:S603.
11. Gavin AL, Aït-Azzouzene D, Ware CF, Nemazee D: ΔBAFF, an alternate splice isoform that regulates receptor binding and biopresentation of the B cell survival cytokine, BAFF. J Biol Chem 2003, 278:38220-38228.
12. Klippel JH: Primer on the Rheumatic Diseases 12th edition. Atlanta: Arthritis Foundation; 2001.
13. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH: Derivation of the SLEDAI: A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992, 35:630-640.
14. Nardelli B, Belvedere O, Roschke V, Moore PA, Olsen HS, Migone TS, Sosnovtseva S, Carrell JA, Feng P, Giri JG, Hilbert DM: Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood 2001, 97:198-204.
15. Thompson JS, Schneider P, Kalled SL, Wang L, Lefevre EA, Cachero TG, MacKay F, Bixler SA, Zafari M, Liu ZY, et al.: BAFF binds to the tumor necrosis factor receptor-like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population. J Exp Med 2000, 192:129-135.
16. Do RK, Hatada E, Lee H, Tourigny MR, Hilbert D, Chen-Kiang S: Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response. J Exp Med 2000, 192:953-964.
17. Batten M, Groom J, Cachero TG, Qian F, Schneider P, Tschopp J, Browning JL, Mackay F: BAFF mediates survival of peripheral immature B lymphocytes. J Exp Med 2000, 192:1453-1466.
18. Harless SM, Lentz VM, Sah AP, Hsu BL, Clise-Dwyer K, Hilbert DM, Hayes CE, Cancro MP: Competition for BLyS-mediated signaling through Bcmd/ BR3 regulates peripheral B lymphocyte numbers. Curr Biol 2001, 11:1986-1989.
19. Hsu BL, Harless SM, Lindsley RC, Hilbert DM, Cancro MP: Cutting edge: BLyS enables survival of transitional and mature B cells through distinct mediators. J Immunol 2002, 168:5993-5996.
20. Avery DT, Kalled SL, Ellyard JI, Ambrose C, Bixler SA, Thien M, Brink R, Mackay F, Hodgkin PD, Tangye SG: BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. J Clin Invest 2003, 112:286-297.
21. Hatada EN, Do RK, Orlofsky A, Liou HC, Prystowsky M, MacLennan IC, Caamano J, Chen-Kiang S: NF-κB1 p50 is required for BLyS attentuation of apoptosis but dispensible for processing of NF-κB2 p100 to p52 in quiescent mature B cells. J Immunol 2003, 171 761-768.
22. Scapini P, Nardelli B, Nadali G, Calzetti F, Pizzolo G, Montecucco C, Cassatella MA: G-CSF-stimulated neutrophils are a prominent source of functional BLyS. J Exp Med 2003, 197:297-302.
23. Scapini P, Carletto A, Nardelli B, Calzetti F, Roschke V, Merigo F, Tamassia N, Pieropan S, Biasi D, Sbarbati A, et al.: Proinflammatory mediators elicit the secretion of the intracellular B-lymphocyte stimulator pool (BLyS) that is stored in activated neutrophils: Implications for inflammatory diseases. Blood 2005, 105:830-837.
24. Tan SM, Xu D, Roschke V, Perry JW, Arkfeld DG, Ehresmann GR, Migone TS, Hilbert DM, Stohl W: Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis. Arthritis Rheum 2003, 48:982-992.
25. Stohl W, Xu D, Kim KS, Koss MN, Jorgensen TN, Deocharan B, Metzger TE, Bixler SA, Hong YS, Ambrose CM, et al.: BAFF overexpression and accelerated glomerular disease in mice with an incomplete genetic predisposition to systemic lupus erythematosus. Arthritis Rheum 2005, 52:2080-2091.
26. Davis JC Jr, Gross J, Gescuk B, Harder B, Wofsy D: zTNF4 and soluble TACI receptor levels in serum and urine may reflect disease activity in patients with SLE. Arthritis Rheum 2001, 44:S99.
27. Carter RH, Zhao H, Liu X, Pelletier M, Chatham W, Kimberly R, Zhou T: Expression and occupancy of BAFF-R on B cells in systemic lupus erythematosus. Arthritis Rheum 2005 in press.
28. Cambridge G, Stohl W, Migone T-S, Hilbert DM, Leandro MJ, Edwards JCW: Circulating levels of B lymphocyte stimulator (BLyS) in patients with rheumatoid arthritis following rituximab treatment: Relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum 2006 in press.
29. Cambridge G, Leandro MJ, Stohl W, Migone TS, Hilbert DM, Isenberg DA, Teodorescu M, Ehrenstein MR, Edwards JC: Serological changes following B cell depletion therapy in systemic lupus erythematosus: relationship with BLyS. Arthritis Rheum 2004, 50 S645-S646.
30. Budman DR, Merchant EB, Steinberg AD, Doft B, Gershwin ME, Lizzio E, Reeves JP: Increased spontaneous activity of antibody-forming cells in the peripheral blood of pateints with active SLE. Arthritis Rheum 1977, 20:829-833.
31. Ginsburg WW, Finkelman FD, Lipsky PE: Circulating and pokeweed mitogen-induced immunoglobulin-secreting cells in systemic lupus erythematosus. Clin Exp Immunol 1979, 35:76-88.
32. Klinman DM, Shirai A, Ishigatsubo Y, Conover J, Steinberg AD: Quantitation of IgM- and IgG-secreting B cells in the peripheral blood of patients with systemic lupus erythematosus. Arthritis Rheum 1991, 34:1404-1410.
33. Odendahl M, Jacobi A, Hansen A, Feist E, Hiepe F, Burmester GR, Lipsky PE, Radbruch A, Dörner T: Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J Immunol 2000, 165:5970-5979.
34. high plasma cells and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 2003, 48:1332-1342.
35. Litinskiy MB, Nardelli B, Hilbert DM, He B, Schaffer A, Casali P, Cerutti A: DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol 2002, 3:822-829.
36. Balázs M, Martin F, Zhou T, Kearney J: Blood dendritic cells interact with splenic marginal zone B cells to initiate T-independent immune responses. Immunity 2002, 17:341-352.
37. Lesley R, Xu Y, Kalled SL, Hess DM, Schwab SR, Shu HB, Cyster JG: Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity 2004, 20:441-453.
38. Thien M, Phan TG, Gardam S, Amesbury M, Basten A, Mackay F, Brink R: Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 2004, 20:785-798.
39. Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA: An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 2002, 46:2673-2677.
40. Gross JA, Dillon SR, Mudri S, Johnston J, Littau A, Roque R, Rixon M, Schou O, Foley KP, Haugen H, et al.: TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease: impaired B cell maturation in mice lacking BLyS. Immunity 2001, 15:289-302.
41. Schiemann B, Gommerman JL, Vora K, Cachero TG, Shulga-Morskaya S, Dobles M, Frew E, Scott ML: An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 2001, 293:2111-2114.
42. Gorelik L, Cutler AH, Thill G, Miklasz SD, Shea DE, Ambrose C, Bixler SA, Su L, Scott ML, Kalled SL: Cutting edge: BAFF regulates CD21/35 and CD23 expression independent of its B cell survival function. J Immunol 2004, 172:762-766.